BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15817604)

  • 1. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
    González-Martín AJ; Calvo E; Bover I; Rubio MJ; Arcusa A; Casado A; Ojeda B; Balañá C; Martínez E; Herrero A; Pardo B; Adrover E; Rifá J; Godes MJ; Moyano A; Cervantes A
    Ann Oncol; 2005 May; 16(5):749-55. PubMed ID: 15817604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
    Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
    Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma.
    Balbi G; Di Prisco L; Musone R; Menditto A; Cassese E; Balbi C; Cardone A
    Eur J Gynaecol Oncol; 2002; 23(4):347-9. PubMed ID: 12214742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer.
    Chen WC; Huang HJ; Chang TC; Chou HH
    Taiwan J Obstet Gynecol; 2020 Jan; 59(1):21-27. PubMed ID: 32039795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
    Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
    Vergote I; Bergfeldt K; Franquet A; Lisyanskaya AS; Bjermo H; Heldring N; Buyse M; Brize A
    Gynecol Oncol; 2020 Feb; 156(2):293-300. PubMed ID: 31826802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
    Shawky H; Tawfik H; Hewidy M
    J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
    Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.